A unique value proposition to anticipate tumor’s evolution.
A unique value proposition to anticipate tumor’s evolution.
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua.
STC allogeneic vaccine
Mimicking patient’s mechanism of relapse to increase panel of targets. Validation based on proteome. (LC/MS)
Invasive: tumor biopsy needed, HLA restriction.
Limited / Validation based on gene
extrapolation. (NGC platform)
Non immunogenic targets, Potential
safety issues with viral vectors.
“Patient / Patient”
Complex, long and costly.
Exemple of treatments with a biological rational to combine with STC 1010
Checkpoint inhibitors,ADC, BiSpecificmAb, TLR restores the anticancer immunity
5FU, Bevacizumab and Cyclophosphamide low dose, radiotherapy.
Bevacizumab Facilitates infiltration of CD8+ lymphocytes into tumors
GM-CSF low dose: Recruits APC at injection point and mature DCs.
Checkpoint inhibitors, ADC TLR Promotes T cell priming and activation.
Chemokyne cytokine TLR : Increase trafficking of T cell
A deep understanding of cancer’s complexity to offer a new kind of Accessible precision treatment in oncology
For clinical trials & collaborative study
Strong protection worldwide
TO efficiently treating solid tumors
To position Brenus as a leader in immuno-oncology
The technological relay to effectively treat solid tumors and avoid cancer recurrence. Brenus Pharma is now anticipating scientific and clinical collaboration models which aimed at synergizing pipeline development in immuno-oncology.
Brenus’ manufacturing process overpasses the lack of immunogenicity & educates the immune system with visible and multi-specific targets
Selection criteria of starting material (Allogeneic tumor cell lines)
Brenus’ manufacturing process overpasses the lack of antigenicity & educates the immune system with a broad & higher quality range of tumor antigens